METARAMINOL Synthesis, SAR, MCQ,Structure,Chemical Properties and Therapeutic Uses

METARAMINOL Synthesis, SAR, MCQ,Structure,Chemical Properties and Therapeutic Uses


IUPAC nomenclature




Metaraminol is a selective α1- adrenergic agonist.

Physiochemical Properties

1 Molecular weight 167.2 g/mol
2 Physical appearance Present in solid form
3 Melting point 107.5°C
4 Solubility 1000g/L
5 Octanol/water partition coefficient -0.27
6 Presence of ring Benzene ring
7 Number of chiral centers 2


Mechanism of Action

i. Metaraminol acts as α1-drenergic agonist and produces peripheral vasoconstriction.

ii. It inhibits adenyl cyclase and thus, inhibition of the production of cAMP

iii. It also releases norepinephrine from its storage sites indirectly.

iv. All results in increase in systemic blood pressure. [1]

Structure Activity Relationship

 The SAR of Adrenergic agonist can be discussed as follows:

  • Primary or secondary aliphatic amine separated by two carbons from a substituted benzene ring is essential for the high agonist activity.
  • The hydroxyl substituted carbon must be in the R configuration for the maximal direct activity.

R1 substitution:

  • When R1 is increased in size, activity of alpha receptors decreases and activity of the beta receptors increases
  • Activity of both alpha and beta receptors is maximum when R1 is methyl group.
  • Alpha agonist activity decreases when R1 is larger than methyl, and went negligible when R1 is isopropyl.
  • Large lipophillic groups can afford compounds with alpha blocking activity.
  • N-substituent provides selectivity for different receptors.
  • Arylalkyl group can provide beta selectivity, increased cell penetration and increased lipophillicity for the longer duration of action.

R2 substitution:

  • Ethyl group can eliminate the alpha activity of the drug.
  • Erythrostero isomers have maximal activity.
  • The additional methyl group makes the drug more selective for the alpha2

R3 substitution on the aromatic ring:

  • 3’,4’-dihydroxy substituted benzene ring has poor oral activity.
  • 3’, 5’-dihydroxy compounds are orally active.
  • At least one of the groups is required which can form hydrogen bonds. And if only one group is present then it is preferred at 4’ position to retain the beta2

If phenyl group has no phenolic substituent then it may act directly or indirectly. [2]

Method of synthesis

i. 1-(3-hydroxyphenyl)propan-1-one is reacted with chlorobenzene to give 1-(3-(benzyloxy)phenyl)propan-1-one.

ii. Reaction of the above compound with BnONO gives (E)-1-(3-(benzyloxy)phenyl)-2-(hydroxyimino)propan-1-one.

iii. When the latter compound undergoes reduction, it produces 2-amino-1-(3-(benzyloxy) phenyl)propan-1-ol.

iv. Latter compound further undergoes reduction to give Metaraminol.

Therapeutic Uses

Ephedrine  is used:

  • For prevention and treatment of acute hypotensive state occurring with spinal anesthesia.
  • As an adjunctive treatment of hypotension due to hemorrhage

Side Effects

Side effects of metaraminol are:

  • Sinus tachycardia
  • Ventricular tachycardia
  • Arrhythmias
  • Tissue necrosis
  • Nausea
  • Vomiting
  • Anxiety
  • Dizziness
  • Nervousness


Q.1 Complete the given below sentence.

“Metaraminol acts on α-adrenergic receptors and leads to ……… of adenylcyclase, thus inhibition of production of ………. .

a) Stimulation, ATP

b) Inhibition, cAMP

c) Stimulation, cAMP

d) Inhibition, ATP

Q.2 Metaraminol is given to patient during?

a) Hypotension

b) Hypertension

c) Tachycardia

d) None of these

Q.3 Which amongst the following are the correct statements with respect to the SAR of drug Metaraminol?

I. Primary or secondary aliphatic amine separated by two carbons from a substituted benzene ring is essential for the high agonist activity.

II. The hydroxyl substituted carbon must be in the R configuration for the maximal direct activity.

a) I

b) II

c) I, II

d) None

Q.4 The starting chemicals required for the synthesis of drug Metaraminol?

a) 1-(3-hydroxyphenyl)propan-1-one

b) 3-(4-nitrophenyl)butanone

c) Both a) and b) are required

d) None of these

Q.5 Correct sequence for the True/False for the physiochemical properties of the drug Metaraminol?

I. Molecular weight is 121.25 gm/mol

II. Its solubility is 1000 gm/L

III. Melts at room temperature.

IV. Cyclohexyl ring is present in the structure.





Q.6 Correct statements for the IUPAC nomenclatures of the drugs are?

I. Metaraminol: 3-[(1R,2S)-2-amino-1-hydroxypropyl]phenol

II. Pseudoephedrine: (S,S)-2-methylamino-1-phenylpropan-1-ol.

III.  Hydroxyamphetamine: (RS)-[4-(1-Hydroxy-2-tert-butylamino-ethyl)-2-(4-methylbenzoyl)oxy-phenyl] 4-methylbenzoate

a) I, III

b) I, II

c) I, II, III

d) II, III

 Q.7 Match the following drugs with their correct classifications-

i. Metaraminol A. Mixed-acting sympathomimetic
ii. Amphetamine B. ß2-arenergic agonist
iii. Silodosin C. Selective α1-adenergic agonist
iv. Pirbuterol D. Selective α2-adrenergic antagonist

 a) i-D, ii-A, iii-C, iv-B

b) i-C, ii-A, iii-B, iv-D

c) i-B, ii-D, iii-C, iv-A

d) i-C, ii-A, iii-D, iv-B


For More Standard and Quality Question Bank you can Join Our Test Series Programme for GPAT, NIPER JEE, Pharmacist Recruitment Exam, Drug Inspector Recruitment Exams, PhD Entrance Exam for Pharmacy











[1] HARRISON DC, CHIDSEY CA, BRAUNWALD E. Studies on the mechanism of action of metaraminol (Aramine). Annals of internal medicine. 1963 Sep 1;59(3):297-305.

[2] Lemke TL, Zito SW, Roche VF, Williams DA. Essentials of Foye’s principles of medicinal chemistry. Wolters Kluwer; 2017, 348-352


Leave a Reply

Your email address will not be published. Required fields are marked *

Free Video Lectures of Pharmacy Exams
Watch now
Admission open 2024 Clinical Research & Pharmacovigilance Courses
Apply now

Developed By Connect Globes